Cordis Recruits Guidant To Block Taxus, Develop Combined Delivery System
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Cordis is betting that its drug-eluting stent marketing alliance with Guidant will allow it to match Boston Scientific's sales presence in U.S. cath labs
You may also be interested in...
Medtronic Stent Patent Ruling Makes DES Vulnerable; Will Guidant Cut Deal?
Medtronic will appeal a Delaware federal court patent infringement ruling against its Driver and S7 coronary stents and challenge the validity of Guidant's Lau patent, the firm says
Medtronic Stent Patent Ruling Makes DES Vulnerable; Will Guidant Cut Deal?
Medtronic will appeal a Delaware federal court patent infringement ruling against its Driver and S7 coronary stents and challenge the validity of Guidant's Lau patent, the firm says
Will Guidant Return To Pharma Roots After 10 Years As Stand-Alone Entity?
Guidant's cardiac surgery device and guiding catheter segments offer an attractive fit with Johnson & Johnson, though ICD market access and drug-eluting stent synergies would be the true drivers of any merger